ECSP16090450A - HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1) - Google Patents
HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1)Info
- Publication number
- ECSP16090450A ECSP16090450A ECIEPI201690450A ECPI201690450A ECSP16090450A EC SP16090450 A ECSP16090450 A EC SP16090450A EC IEPI201690450 A ECIEPI201690450 A EC IEPI201690450A EC PI201690450 A ECPI201690450 A EC PI201690450A EC SP16090450 A ECSP16090450 A EC SP16090450A
- Authority
- EC
- Ecuador
- Prior art keywords
- humanized antibodies
- ceacam1
- antibodies against
- adhesion molecule
- cellular adhesion
- Prior art date
Links
- 101710145634 Antigen 1 Proteins 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 108010062802 CD66 antigens Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan anticuerpos humanizados, capaces de unión específica a moléculas de CEACAM1 humana que contienen mutaciones restauradoras de humano a murino en regiones variables distintas de CDR, y sus secuencias codificadoras de polinucleótidos; también se proporcionan composiciones farmacéuticas que comprenden estos anticuerpos, así como sus métodos de su uso para tratar y diagnosticar cáncer y otras condiciones.Humanized antibodies are provided, capable of specific binding to human CEACAM1 molecules containing human to murine restorative mutations in variable regions other than CDRs, and their polynucleotide coding sequences; Pharmaceutical compositions comprising these antibodies are also provided, as well as methods of their use to treat and diagnose cancer and other conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984786P | 2014-04-27 | 2014-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP16090450A true ECSP16090450A (en) | 2017-06-30 |
Family
ID=72643836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201690450A ECSP16090450A (en) | 2014-04-27 | 2016-11-24 | HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1) |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP16090450A (en) |
-
2016
- 2016-11-24 EC ECIEPI201690450A patent/ECSP16090450A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000282A (en) | HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1) | |
| NI201700012A (en) | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | |
| PE20210288A1 (en) | ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS | |
| MX2020012797A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use. | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| EA201690167A1 (en) | HUMANIZED OR CHEMICAL ANTIBODIES TO CD3 | |
| SA517381703B1 (en) | Anti-C10orf54 Antibodies And Uses Thereof | |
| CO2019001246A2 (en) | Anti-PD-1 antibodies, a production method and a method for its use | |
| EA202190609A1 (en) | ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G | |
| EA201892193A1 (en) | CHEMICAL RECEPTORS TO FLT3 AND METHODS OF THEIR APPLICATION | |
| EA201892362A1 (en) | AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS | |
| EA201890443A1 (en) | BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| EA201591091A1 (en) | Antigen-binding proteins for BCMA | |
| EA202191785A1 (en) | ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION | |
| EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
| MX2019007554A (en) | BINDING PROTEINS TO THE ANTI-NEUROPYLIN ANTIGEN, AND THEIR METHODS OF USE. | |
| EA201790719A1 (en) | BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2018005061A (en) | Glycan-interacting compounds and methods of use. | |
| EA201792581A1 (en) | METHODS OF APPLICATION OF BISPECIFIC CD33- and CD3-BINDING PROTEINS | |
| BR112018010279A2 (en) | new anti-emr2 antibodies and methods of use | |
| MX389103B (en) | TICAGRELOR ANTIBODIES AND METHODS OF USE. | |
| BR112018012884A2 (en) | new anti-mmp16 antibodies and methods of use | |
| EA201990978A1 (en) | ANTIBODIES AGAINST PD-1 |